Novo Nordisk, the manufacturer of the weight-loss and diabetes medication Ozempic, has filed a lawsuit against its U.S. competitor, Eli Lilly. The legal action centers on an advertising campaign launched by Eli Lilly that compares the two companies' respective products.
Novo Nordisk alleges that Eli Lilly is utilizing inaccurate data to support its claims in these advertisements. The lawsuit seeks to address these marketing practices, which the plaintiff contends misrepresent the performance and efficacy of the competing medications.
In-depth summary · AI, neutral